Patient Support Services Contact Us
Products_and_Pipeline_Banner

Addressing Important Unmet Needs

At Coherus, we put patients first. We're dedicated to improving lives by expanding access to biologics. Our robust pipeline is bringing high-value treatments to patients in need. We have the assets, expertise, and insights to bring high-quality products to patients around the world.

Product/
Candidate
DescriptionPre-ClinicalPhase 1/2Phase 3/
BLA Enabling
ApprovedStatus
ONCOLOGY PIPELINE
Product/
Candidate
DescriptionPre-ClinicalPhase 1/2Phase 3
/BLA Enabling
ApprovedStatus
UDENYCA®pegfilgrastim
biosimilar

Approved by the US Food and Drug Administration and European Commission

Anti-TNF Pipeline
Product/
Candidate
DescriptionPre-ClinicalPhase 1/2Phase 3/
BLA Enabling
ApprovedStatus
CHS-1420adalimumab
biosimilar

Phase 3 clinical studies in psoriasis completed

Focus on securing competitive launch in US market

CHS-0214etanercept
biosimilar

Phase 3 clinical studies in psoriasis and RA completed

Ophthalmology Pipeline
Product/
Candidate
DescriptionPre-ClinicalPhase 1/2Phase 3/
BLA Enabling
ApprovedStatus
 ranibizumab
biosimilar

Phase 3 clinical studies in wet AMD completed

CHS-2020aflibercept
biosimilar

Pre-clinical development

METABOLIC PIPELINE
Product/
Candidate
DescriptionPre-ClinicalPhase 1/2Phase 3/
BLA Enabling
ApprovedStatus
CHS-131 Selective PPAR-gamma modulator

Initiating Phase 2 studies in NASH

Completed Phase 2 studies in Type II diabetes and multiple sclerosis

CHS-5217
trastuzumab (Avastin)
ORIGINATOR APPROVED INDICATIONSstatustiming
CHS-0214
etanercept (Enbrel)
ORIGINATOR APPROVED INDICATIONSstatustiming
CHS-1420
adalimumab (HUMIRA)
ORIGINATOR APPROVED INDICATIONSstatustiming
CHS-3551
ranibizumab (Lucentis)
ORIGINATOR APPROVED INDICATIONSstatustiming